Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
A combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of treatment with NIVO + IPI has been reported in Japanese cohorts. We evaluated the clinical effica...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/12/583 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241146410762240 |
|---|---|
| author | Tomoki Taniguchi Koji Iinuma Kei Kawada Takashi Ishida Kimiaki Takagi Masayuki Tomioka Makoto Kawase Kota Kawase Keita Nakane Yuki Tobisawa Takuya Koie |
| author_facet | Tomoki Taniguchi Koji Iinuma Kei Kawada Takashi Ishida Kimiaki Takagi Masayuki Tomioka Makoto Kawase Kota Kawase Keita Nakane Yuki Tobisawa Takuya Koie |
| author_sort | Tomoki Taniguchi |
| collection | DOAJ |
| description | A combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of treatment with NIVO + IPI has been reported in Japanese cohorts. We evaluated the clinical efficacy of NIVO + IPI treatment. Patients with mRCC who received NIVO + IPI at nine Japanese facilities between August 2018 and March 2023 were enrolled in this study. The primary endpoint in this study was the assessment of oncological outcomes in patients with mRCC who received NIVO + IPI. Eighty-four patients with mRCC were enrolled. The median follow-up period was 18.3 months, and median progression-free and overall survival were 13.3 and 50.9 months, respectively. The objective response rate was 47.6%, and the disease control rate was 78.6%. To our knowledge, this is the largest study that evaluates Japanese patients with mRCC receiving NIVO + IPI treatment. In this study, the real-world oncological outcomes after NIVO + IPI treatment were comparable to those in the CheckMate 214 study. |
| format | Article |
| id | doaj-art-fa23d7e1b4e14d8fbe470d3bfbf96c65 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-fa23d7e1b4e14d8fbe470d3bfbf96c652025-08-20T02:00:41ZengMDPI AGCurrent Oncology1198-00521718-77292024-12-0131127914792310.3390/curroncol31120583Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in JapanTomoki Taniguchi0Koji Iinuma1Kei Kawada2Takashi Ishida3Kimiaki Takagi4Masayuki Tomioka5Makoto Kawase6Kota Kawase7Keita Nakane8Yuki Tobisawa9Takuya Koie10Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noisiki, Gifu 500-8717, JapanDepartment of Urology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu 500-8513, JapanDepartment of Urology, Daiyukai Hospital, 1-9-9 Sakura, Ichinomiya 491-8551, JapanDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, JapanA combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of treatment with NIVO + IPI has been reported in Japanese cohorts. We evaluated the clinical efficacy of NIVO + IPI treatment. Patients with mRCC who received NIVO + IPI at nine Japanese facilities between August 2018 and March 2023 were enrolled in this study. The primary endpoint in this study was the assessment of oncological outcomes in patients with mRCC who received NIVO + IPI. Eighty-four patients with mRCC were enrolled. The median follow-up period was 18.3 months, and median progression-free and overall survival were 13.3 and 50.9 months, respectively. The objective response rate was 47.6%, and the disease control rate was 78.6%. To our knowledge, this is the largest study that evaluates Japanese patients with mRCC receiving NIVO + IPI treatment. In this study, the real-world oncological outcomes after NIVO + IPI treatment were comparable to those in the CheckMate 214 study.https://www.mdpi.com/1718-7729/31/12/583renal cell carcinomanivolumabipilimumabJapanese cohort |
| spellingShingle | Tomoki Taniguchi Koji Iinuma Kei Kawada Takashi Ishida Kimiaki Takagi Masayuki Tomioka Makoto Kawase Kota Kawase Keita Nakane Yuki Tobisawa Takuya Koie Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan Current Oncology renal cell carcinoma nivolumab ipilimumab Japanese cohort |
| title | Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan |
| title_full | Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan |
| title_fullStr | Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan |
| title_full_unstemmed | Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan |
| title_short | Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan |
| title_sort | real world oncological outcomes of nivolumab plus ipilimumab in advanced or metastatic renal cell carcinoma a multicenter retrospective cohort study in japan |
| topic | renal cell carcinoma nivolumab ipilimumab Japanese cohort |
| url | https://www.mdpi.com/1718-7729/31/12/583 |
| work_keys_str_mv | AT tomokitaniguchi realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT kojiiinuma realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT keikawada realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT takashiishida realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT kimiakitakagi realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT masayukitomioka realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT makotokawase realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT kotakawase realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT keitanakane realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT yukitobisawa realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan AT takuyakoie realworldoncologicaloutcomesofnivolumabplusipilimumabinadvancedormetastaticrenalcellcarcinomaamulticenterretrospectivecohortstudyinjapan |